Ii-Key/HER2/neu cancer vaccine: Phase I data

In a dose-escalation, U.S. Phase I trial (Study I-03) in 15 patients, AE37 with and without GM-CSF elicited dose-dependent immune responses. Patients received six immunizations at monthly intervals of...